Genomic Assay Predicts Probability of Heart Transplant Rejection
By LabMedica International staff writers Posted on 05 Mar 2014 |
Results obtained over time by a gene expression assay used to monitor heart transplant patients for signs of rejection may be able to predict the likelihood of rejection in the future.
The AlloMap Molecular Expression Test, which is manufactured and performed by the biomedical company XDx (Brisbane, CA, USA), is an in vitro diagnostic multivariate index assay (IVDMIA) testing service. The assay, which is performed in a single laboratory, assesses the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing may be used to evaluate transplant patients aged 15 years or older from at least two months after the transplant. It is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.
AlloMap, which measures the expression levels of 11 rejection-related genes from a patient's blood sample, received clearance from the [US] Food and Drug Administration (FDA) in 2008 and it is now routinely used by a majority of American heart transplant centers to monitor low-risk patients during follow-up care, resulting in a substantial reduction in the number of heart-muscle biopsies.
Investigators at the University of California, Los Angeles (USA) recently evaluated data obtained by a study of 600 heart transplant recipients who had been monitored by routine biopsy or with the AlloMap test. They found that the variability of a heart recipient's gene expression profiling test scores over time could provide prognostic utility. This information was independent of the probability of acute cellular rejection at the time of testing.
"The AlloMap was the first FDA-cleared test allowing transplant centers to rule out rejection at the time of the visit," said first author Dr. Mario Deng, professor of medicine at the University of California, Los Angeles. "But until now, it has never been used to predict future events. For the first time, we can use genomic testing over multiple patient visits to go beyond intuition to understand not just how patients are doing now but how they are likely to be a few months from now. It is another step toward personalized medicine."
The study was published in the January 31, 2014, online edition of the journal Transplantation.
Related Links:
XDx
University of California, Los Angeles
The AlloMap Molecular Expression Test, which is manufactured and performed by the biomedical company XDx (Brisbane, CA, USA), is an in vitro diagnostic multivariate index assay (IVDMIA) testing service. The assay, which is performed in a single laboratory, assesses the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing may be used to evaluate transplant patients aged 15 years or older from at least two months after the transplant. It is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.
AlloMap, which measures the expression levels of 11 rejection-related genes from a patient's blood sample, received clearance from the [US] Food and Drug Administration (FDA) in 2008 and it is now routinely used by a majority of American heart transplant centers to monitor low-risk patients during follow-up care, resulting in a substantial reduction in the number of heart-muscle biopsies.
Investigators at the University of California, Los Angeles (USA) recently evaluated data obtained by a study of 600 heart transplant recipients who had been monitored by routine biopsy or with the AlloMap test. They found that the variability of a heart recipient's gene expression profiling test scores over time could provide prognostic utility. This information was independent of the probability of acute cellular rejection at the time of testing.
"The AlloMap was the first FDA-cleared test allowing transplant centers to rule out rejection at the time of the visit," said first author Dr. Mario Deng, professor of medicine at the University of California, Los Angeles. "But until now, it has never been used to predict future events. For the first time, we can use genomic testing over multiple patient visits to go beyond intuition to understand not just how patients are doing now but how they are likely to be a few months from now. It is another step toward personalized medicine."
The study was published in the January 31, 2014, online edition of the journal Transplantation.
Related Links:
XDx
University of California, Los Angeles
Latest Molecular Diagnostics News
- Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis
- New Gene Tool to Enable Earlier Detection and Treatment of Cardiometabolic Diseases
- Genetic Tool Predicts Lithium Responsiveness in Bipolar Disorder Patients
- Genetic Testing Benefits Critically Ill Adults
- Testing Blood Samples for Proteins Can Reveal Malaria Severity
- Blood Test Detects Multiple Sclerosis Risk Years Before Onset of Symptoms
- Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age
- RNA Screening Test Could Detect Colon Polyps Before They Become Cancerous
- New RT-LAMP Assay Offers Affordable and Reliable Pathogen Detection for Resource-Limited Settings
- New Biomarker Panel to Enable Early Detection of Pancreatic Cancer
- Ultrarapid Whole Genome Sequencing for Neonatal and Pediatric Patients Delivers Results In 48 Hours
- AI-Enabled Blood Test Demonstrates Diagnostic, Prognostic and Predictive Utility Across Cancer Continuum
- DNA Methylation Signatures of Aging Could Help Assess Mortality Risk
- Molecular Diagnostics System Provides Lab-Quality Results at POC
- Cellular Signature Identifies Patients with Treatment Resistant Prostate Tumors
- MCED Could Be Valuable Supplement to Traditional Cancer Screening Approaches
Channels
Clinical Chemistry
view channel
Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
Parkinson’s disease is notoriously difficult to diagnose in its early stages, as motor symptoms do not appear until later in the progression of the disease. The ability to detect the disease up to seven... Read more
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy
To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis
Cardiovascular disease is the leading cause of death worldwide, and atherosclerosis plays a critical role in its development. This chronic condition, characterized by the hardening and narrowing of arteries... Read more
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Accurately Determines Breast Cancer Prognosis
A new study has found that cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to treatment. The research, published in the journal Patterns,... Read more
Powerful New Tool Improves Tissue Cancer Analysis
Studying the mix of cell types in human tissue is crucial for understanding diseases like cancer, but it presents significant challenges in both accuracy and scalability. The tumor microenvironment, composed... Read moreTechnology
view channel
Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells
A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Safer, Portable and Low-Cost Imaging Solution to Revolutionize Biomedical Diagnostics
In diagnosing diseases and monitoring treatment, accurate and quick detection of temperature within biological tissues can be crucial, especially in early disease detection. Conventional methods such as... Read more
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read moreIndustry
view channel
QuidelOrtho and BÜHLMANN Collaborate on Gastrointestinal Biomarker Tests
QuidelOrtho Corporation (San Diego, CA, USA) and BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) have announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's... Read more